Metronidazole Noridem (Metronidazole)

Metronidazole enters susceptible anaerobic microorganisms and is reduced by their internal electron‑transport proteins. This reduction creates nitro radical anions that damage DNA and inhibit nucleic acid synthesis, ultimately leading to microbial cell death and resolution of the infection.

The specific dose and duration of Metronidazole Noridem are determined by the prescribing clinician based on the infection type, severity, patient age, weight, and renal or hepatic function. Dosing regimens can vary widely, so the prescriber sets the appropriate schedule.

Safety data for metronidazole during pregnancy are limited, and the pregnancy category is listed as unknown. It should be used only if the potential benefit justifies any potential risk to the fetus. Caution is also advised during breastfeeding, as the drug can be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Metronidazole is a nitroimidazole that specifically targets anaerobic organisms, offering rapid bactericidal activity. Compared with broad‑spectrum beta‑lactams, it provides a narrower spectrum focused on anaerobes, often with fewer drug‑resistance concerns. However, clinicians may combine it with other agents for mixed‑flora infections to ensure comprehensive coverage.

Metronidazole Noridem should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the vial from moisture, direct sunlight, and extreme temperature fluctuations. Do not freeze. Follow standard aseptic techniques when preparing the solution for intravenous infusion.

Metronidazole Noridem is given by intravenous infusion. The sterile vial is typically diluted in a compatible IV fluid (such as 5 % dextrose or normal saline) and administered over a period specified by the prescriber, often ranging from 30 minutes to several hours depending on the clinical scenario.

Serious adverse events include seizures, peripheral neuropathy, severe allergic reactions (anaphylaxis), Stevens‑Johnson syndrome, hepatotoxicity, and neutropenia. Patients should be instructed to seek immediate medical attention if they experience neurological symptoms, skin eruptions, jaundice, or signs of severe infection.

Metronidazole Noridem is contraindicated in patients with a known hypersensitivity to metronidazole or other nitroimidazole compounds. Caution is advised for individuals with severe hepatic impairment, those receiving concurrent alcohol, and patients with a history of seizures or peripheral neuropathy, unless the benefits outweigh the risks.